Development of simvastatin electrospun fibers: a novel approach for sustained drug delivery
- 166 Downloads
In the present investigation simvastatin electrospun fibers were developed using electrospinning apparatus with drug–polymer w/w ratios of 1:1, 1:2, 1:3 and 1:4. Also solid mixtures were prepared with same ratios by employing kneading technique as conventional approach for comparison in drug release rate. Polyethylene oxide WSR coagulant 301, a hydrophilic matrix forming polymer, was used as carrier for sustained release of simvastatin. The ability of polyethylene oxide to control the drug release rate in both the formulations was also investigated. Studies were performed to characterize the optimized dosage form. Drug was crystalline in pure form. SEM surface morphology studies as well as powder X-ray diffractometry studies to developed fibers reveals that the crystalline drug was converted into amorphous form after fiber development. No physical incompatibility was found in FTIR and DSC studies of pure drug and physical mixture of drug, polymer. In vitro studies were performed in sodium phosphate buffer (pH 7.0) containing 0.5 % SLS. Simvastatin release was sustained over a period of 12 h in electrospinning fibers developed with drug to polymer w/w ratio 1:4 and 98.86 ± 0.42 % drug release was observed, interestingly with the same ratio there was a burst release of drug was obtained in case of solid mixtures “within span of 1 h”. Polyethylene oxide showed vast difference in drug release rate due to the techniques chosen to prepare formulations. The stability studies were also performed to the optimized product and no significant variance was observed in all the evaluation parameters. From the various mathematical models the drug release kinetics was estimated and found that the drug release followed zero order release rate kinetics with non fickian process as drug release mechanism.
KeywordsSimvastatin fibers Electrospinning process Polyethylene oxide Solid mixtures Kneading method
This article dose not contain any studies with human and animal subjects performed by any of the authors. All authors (S. Betha, B. P. Reddy, M. M. Varma, D. B. Raju, and V. R. M. Kolapalli) declare that they have no conflict of interest. The authors are very much thankful to Biocon Ltd, for providing Simvastatin as gift sample.
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
- Dhawan S, Dhawan K, Varma M, Sinha VR (2005) Applications of polyethylene oxide in drug delivery systems—Part II. Pharm Technol 29:82–96Google Scholar
- Flory PJ (1953) Principles of polymer chemistry. Cornell University Press, New YorkGoogle Scholar
- McClelland CA, Stubbs RJ, Fix JA, Pogany SA, Zentner GM (1991) Enhancement of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductage inhibitor efficacy through administration of a controlled osmotic pump dosage form. Pharm Res 8(7):873–876. doi: 10.1023/A:1015899328105 CrossRefPubMedGoogle Scholar
- Peppas NA (1985) Analysis of Fickian and Non-Fickian drug release from polymers. Pharma Acta Helv 60:110–111Google Scholar
- Robinson JR, Lee VHL (1987) Controlled drug delivery: fundamentals and applications. 2nd edn. 390. DekkerGoogle Scholar